Dec. 11 at 4:03 PM
$MDCX AI Overview
Medicus Pharma is developing SkinJect, a non-surgical, dissolvable microneedle patch delivering chemotherapy to treat basal cell skin cancer, offering a potential alternative to invasive surgery like Mohs. This transdermal patch aims to provide an office-based, localized treatment, showing promise in clinical trials with high clearance rates, potentially revolutionizing skin cancer care with better patient comfort and accessibility, and is progressing towards FDA approval with an estimated commercial availability around 2027.
I Hope One Of These Companies Likes Our Product!!!
AI Overview
Major Pharmaceutical Companies (Immunotherapy & Systemic Treatments)
Merck & Co.: Leader with Keytruda (pembrolizumab) for melanoma and other skin cancers.
Bristol Myers Squibb (BMS): Known for checkpoint inhibitors like Opdivo (nivolumab).
Roche (Genentech): A major player in oncology, including skin cancer therapies.
Novartis: Another significant oncology-focused pharmaceutical company.
